22 maj: Accepteret købstilbud på associerede selskaber i Dantax A/S
22 maj: Med tegningsordrer på mere end kr. 57 mio. er Danish Aerospace Co..
22-05-2019 14:00:00

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

Zealand Pharma Press Release – No. 11 / 2019

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes

  • First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled, commercial-ready, pump cartridge has been initiated by a clinical team at Massachusetts General Hospital

  • The iLet Bionic Pancreas System is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes

  • Dasiglucagon is a potential first-in-class stable glucagon analog

Boston, MA and Copenhagen, Denmark, May 22, 2019 – Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL) announced today the first patients dosed in a clinical trial investigating the home-use of dasiglucagon in the iLet™ Bionic Pancreas System.  The iLet, developed by Beta Bionics, is the world’s first autonomous bionic pancreas device — a bihormonal system leveraging lifelong machine learning and artificial intelligence to deliver insulin and glucagon analogs for the autonomous treatment of type 1 diabetes. In addition to dosing insulin, the iLet doses dasiglucagon — a glucagon analog developed by Zealand Pharma with a unique stability profile in a ready-to-use aqueous solution.

This home-use clinical trial is being conducted by Dr. Steven Russell and his clinical research team at the Massachusetts General Hospital. The current trial is designed as a randomized, two-arm, cross-over trial to assess whether the iLet operates as designed. It compares the operational performance of the iLet in its insulin-only configuration to its bihormonal configuration using dasiglucagon in adults with type 1 diabetes.  Secondary objectives of the study include assessing the impact of the insulin-only and bihormonal configurations of the iLet Bionic Pancreas System on glycemic control, quality of life, and treatment satisfaction among study participants, their caregivers, partners, and/or family members.

“The start of this home-use clinical trial with the iLet in its bihormonal configuration — autonomously and independently pumping both insulin and Zealand’s dasiglucagon — marks the achievement of a long-awaited and eagerly anticipated milestone,” said Ed Damiano, Co-founder and President & CEO of Beta Bionics.

Beta Bionics and Zealand Pharma have partnered to carry out several co-development activities with the primary goal of obtaining regulatory approval to use dasiglucagon in the bihormonal configuration of the iLet.  

“Fully automated diabetes care, realized by a dual-hormone artificial pancreas system using insulin together with dasiglucagon, could significantly improve life for millions of people living with type 1 diabetes,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma

 

For further information, please contact:

Beta Bionics

Zealand Pharma

 

Ed Damiano

edamiano@betabionics.com

 

Ed Raskin

eraskin@betabionics.com

 

Investor Relations Contact

Jeremy Feffer

jeremy@lifesciadvisors.com

 

 

Emmanuel Dulac

President and Chief Executive Officer

+45 50 60 36 36

edu@zealandpharma.com

 

Lani Pollworth Morvan

Investor Relations and Communication

+45 50 60 37 78

lpm@zealandpharma.com

 

About the iLet

The iLet bionic pancreas system is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes. The lifelong, machine-learning, mathematical dosing algorithms integrated into the iLet were licensed by Beta Bionics from Boston University.  In previous home-use studies in adults and children with T1D, these algorithms demonstrated dramatic improvements in glycemic control relative to the standard of care.  These improvements included significant reductions in blood-glucose levels, in hypoglycemia, and in intersubject and intrasubject glycemic variability (New England Journal of Medicine. 2014, 371:313-25; Lancet Diabetes and Endocrinology. 2016, 4:233-43; Lancet. 2016, 389:369-80). 

To initialize the iLet, users enter only their body weight.  Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.  The iLet is effectively three medical devices in one.  It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas (insulin and glucagon).  The glucagon-only configuration may be helpful in rare, chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI) and insulinoma syndrome. Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.

About dasiglucagon for use in other indications

Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of severe hypoglycemia, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

About Beta Bionics

Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas system that is driven by machine-learning artificial intelligence to autonomously control glycemia.  These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D. Beta Bionics is a Certified B Corporation™ whose founders—in addition to Ed Damiano—include other parents of children with type 1 diabetes and people with type 1 diabetes.  Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible. 

Beta Bionics is operated out of Boston, Massachusetts and Irvine, California. For further information, please visit www.betabionics.com or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

 

Attachment

Relateret indhold
03 jun - 
Zealand Pharma/Bryan Garnier: Løfter kursmål til 180 kr..
24 maj - 
Zealand Pharma/SHB: Kursmålet løftes mens anbefalingen ..
22 maj - 
Onsdagens aktier: Overbevisende regnskab sendte Simcorp..
Relateret debat
24 jun - 
"Zealand Pharma has yet not found a new CFO. When do yo..
24 jun - 
@Eliot   Der var Q&A med den nye CEO på ..
24 jun - 
Det er lidt vildt. De må virkelig tror på d..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 jun
ZEAL
Zealand Pharma starter website for kort-tarms syndrom patienter (SBS = Short Bowel Syndrom). I mine ..
8
24 jun
ZEAL
ZP er begyndt at rekruttere i et first in human P1-studie med GLP1/GLP2 dual agonist mod SBS:    htt..
3
24 jun
ZEAL
@Eliot   Der var Q&A med den nye CEO på proinvestor i sidste måned - har du læst det? Der er nogle f..
2
24 jun
ZEAL
Det er lidt vildt. De må virkelig tror på dette. De har 64 forsøgspersoner de vil tage ind i forsøge..
2
24 jun
ZEAL
"Zealand Pharma has yet not found a new CFO. When do you expect to be able toannounce this position ..
1
24 jun
ZEAL
Hvornår kommer der en melding på CFO? Jeg havde det indtryk af en ny CFO lige var på trapperne ved Q..
1

Mærsk lancerer nyt onlineprodukt: Vil bryde med overbookinger

25-06-2019 10:36:22
(Korr: ændring i andet afsnit. Ordet "betales" er ændret til "aftales".)A.P. Møller-Mærsk lancerer et nyt onlineprodukt, der skal være med til at gøre transporten af containere mere simpel for kunderne, og som samtidig kan være med til at undgå overbookinger.Produktet går under navnet Maersk Spot, og det sikrer kunderne en garanti for, at fragten bliver lastet, skriver Mærsk i en pressemeddelelse ..

Aktier/tendens: Inspirationen hælder mest til den negative side

25-06-2019 08:15:21
Aktiehandlerne får ændrede kursmål for Chr. Hansen, Ambu, Danske Bank og Carlsberg samt en kontrakt til Maersk Drilling som selskabsspecifikke C25-nyheder til inspiration for den indledende handel tirsdag morgen.To af de fire kursmålsændringer er til den negative side, og det samme er den generelle impuls fra de globale markeder. Der var fald i USA i mandagens handel, og den negative udvikling er ..

Euroinvestor spørger: Tryg-aktien stormer frem, kan den blive ved?

23-06-2019 20:35:00
Hos Euroinvestor mener vi, at den bedste kilde til viden om markedet er aktørerne i markedet.Derfor spørger vi hver måned i vores Privatinvestorundersøgelse (PIU) vores brugere om deres forventninger til markeder og økonomi.Du inviteres hermed til at deltage i undersøgelsen. Alle besvarelser er anonyme, og der er ingen krav om login, kontaktoplysninger eller lignende.Vi håber du vil deltage og ser..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Dybvad: Så alvorlig en sag at vi måtte skride til fyring
2
Vestas/Sydbank: Spansk konkurrent er foran på point i kampen
3
Danske Bank/Nordea: Sænker kursmål med 10 kr.
4
Danske Bank/Erhvervsminister undersøger straf for dårlige råd
5
USA: Trump kræver rentenedsættelser og langer igen ud efter Fed

Relaterede aktiekurser

Zealand Pharma A/S 138,10 0,1% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 138,10 0,1% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. juni 2019 11:38:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-25 11:38:06 - 2019-06-25 11:38:06 - 1 - Website: OKAY